AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

One Bench at a Time

AOBiome today announced it has begun a Phase 2 clinical trial with a therapeutic product candidate based on its proprietary ammonia oxidizing bacteria (AOB) for the treatment of mild to moderate acne vulgaris. The trial with the product candidate, B244, is being conducted under an IND application to the FDA and is the first to test the potential of live bacteria to treat skin disease.

”B244 is classified as a ‘live-topical’, a brand new class of therapeutics to address skin diseases that capitalize on advances in understanding of the skin microbiome and the role of AOB’s play in restoring skin health,” said Spiros Jamas, ScD, AOBiome’s CEO. “This initial clinical trial builds on preclinical studies demonstrating B244’s antibacterial activity and suggesting that B244 acts through multiple mechanisms thereby reducing levels of bacteria linked to acne, and reducing inflammation. The acne trial is the first of several indications we expect to pursue with B244 across a variety of skin disorders.

Read the press release at Business Wire

Upcoming Event

  • San Carlos Open House

    Come to meet MBC BioLabs residents, tour our new space in San Carlos, and hear about our exciting plans for the future. There will be posters from our companies, a live band, and an opportunity to chat with our partners and staff. RSVP In just 4 years, we have helped 116 entrepreneurial teams create fast, focused and frugal biotech companies that have gone on to raise $2.4 billion and counting. With this new facility, we can empower more entrepreneurs with the space and resources they need to tackle world changing science. Come join us in celebrating our newest MBC Biolabs campus and welcome our residents and partners!


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter